U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C9H13N.H2O4S
Molecular Weight 368.491
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXTROAMPHETAMINE SULFATE

SMILES

OS(O)(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC2=CC=CC=C2

InChI

InChIKey=PYHRZPFZZDCOPH-QXGOIDDHSA-N
InChI=1S/2C9H13N.H2O4S/c2*1-8(10)7-9-5-3-2-4-6-9;1-5(2,3)4/h2*2-6,8H,7,10H2,1H3;(H2,1,2,3,4)/t2*8-;/m00./s1

HIDE SMILES / InChI

Molecular Formula C9H13N
Molecular Weight 135.2062
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://blackpoppymag.wordpress.com/substances/dexedrine-dexamphetamine/

Amphetamine is also prescribed in enantiopure and prodrug form as dextroamphetamine and lisdexamfetamine respectively. Lisdexamfetamine is structurally different from amphetamine, and is inactive until it metabolizes into dextroamphetamine. Dextroamphetamine is useful for those with ADHD and Narcolepsy. It improves self-control for people who have a hard time naturally controlling themselves. Dextroamphetamine aids a person learning and memory of words, and perhaps makes the brain stronger. When a person given dextroamphetamine is tested, their brain is extremely active in the brain parts required for the test and radically less active in other parts. Short practice sessions with dextroamphetamine have a greater effect on learning than sessions without dextroamphetamine. Dextroamphetamine raises decision-making scores, improves choices, and changes beliefs about rewards; at the same time, dextroamphetamine barely—if at all—affects guesses of time. Those who feel lower amounts of joy from dextroamphetamine have greater impulsivity improvements compared to those who feel extreme happiness. The drug should be avoided for those who have hypersensitivity to amphetamines, a history of drug abuse, cardiovascular diseases, hypertensive disease, hyperthyroidism, or in those with glaucoma. In 1935, the medical community became aware of the stimulant properties of amphetamine, specifically dextroamphetamine, and in 1937 Smith, Kline, and French introduced Dexedrine tablets, under the tradename Dexedrine. In the United States, Dexedrine tablets were approved to treat narcolepsy, attention disorders, depression, and obesity. Dexedrine, along with other sympathomimetic, was eventually classified as schedule II, the most restrictive category possible for a drug with recognized medical uses. The exact mechanism of action is not known. Dextroamphetamine stimulates the release of norepinephrine from central adrenergic receptors. At higher dosages, it causes release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems by reversal of the monoamine transporters. Dextroamphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). Modulation of serotonergic pathways may contribute to the calming effect.

Originator

Curator's Comment: in 1935, the medical community became aware of the stimulant properties of amphetamine, specifically dextroamphetamine, and in 1937 Smith, Kline, and French introduced Dexedrine tablets, under the tradename Dexedrine.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VYVANSE

Approved Use

VYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1)

Launch Date

2007
Primary
VYVANSE

Approved Use

VYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1)

Launch Date

2007
Primary
DEXEDRINE

Approved Use

Narcolepsy. Attention Deficit Disorder with Hyperactivity. As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.

Launch Date

1980
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
47.9 ng/mL
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
24.7 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
36.6 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
60.7 ng × h/mL
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
431 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12 h
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.1 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 13 - 17
n = 233
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 13 - 17
Sex: M+F
Population Size: 233
Sources: Page: p.8
Disc. AE: Irritability, Decreased appetite...
AEs leading to
discontinuation/dose reduction:
Irritability (1.3%)
Decreased appetite (0.86%)
Insomnia (0.86%)
Sources: Page: p.8
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Disc. AE: Delirium, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Delirium (acute)
Tachycardia
Hypertension
Tachypnea
Creatine kinase increased (mild)
Sources: Page: e771
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Disc. AE: Insomnia, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Insomnia (2%)
Tachycardia (1%)
Irritability (1%)
Hypertension (1%)
Headache (1%)
Anxiety (1%)
Dyspnea (1%)
Sources: Page: p.8
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Disc. AE: Ventricular hypertrophy, Tic...
AEs leading to
discontinuation/dose reduction:
Ventricular hypertrophy (1%)
Tic (1%)
Vomiting (1%)
Psychomotor hyperactivity (1%)
Insomnia (1%)
Rash (1%)
Sources: Page: p.8
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Other AEs: Decreased appetite, Insomnia...
Other AEs:
Decreased appetite (below serious, 29 patients)
Insomnia (below serious, 7 patients)
Weight decreased (below serious, 3 patients)
Irritability (below serious, 6 patients)
Fatigue (below serious, 4 patients)
Nasopharyngitis (below serious, 2 patients)
Sources:
20 mg single, oral
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Other AEs: Nausea...
Other AEs:
Nausea (below serious, 1 patient)
Sources:
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (below serious, 4 patients)
Nausea (below serious, 1 patient)
Vomiting (below serious, 2 patients)
Sources:
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (below serious, 2 patients)
Nausea (below serious, 2 patients)
Sources:
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Other AEs: Diarrhea, Dry mouth...
Other AEs:
Diarrhea (below serious, 6 patients)
Dry mouth (below serious, 25 patients)
Fatigue (below serious, 6 patients)
Feeling jittery (below serious, 10 patients)
Irritability (below serious, 8 patients)
Upper respiratory tract infection (below serious, 5 patients)
Heart rate increased (below serious, 4 patients)
Weight decreased (below serious, 8 patients)
Anorexia (below serious, 4 patients)
Decreased appetite (below serious, 26 patients)
Headache (below serious, 20 patients)
Initial insomnia (below serious, 8 patients)
Insomnia (below serious, 10 patients)
Libido decreased (below serious, 4 patients)
Hyperhidrosis (below serious, 5 patients)
Sources:
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Disc. AE: Abuse, Dependence...
AEs leading to
discontinuation/dose reduction:
Abuse
Dependence
Cardiovascular disorder (NOS) (grade 3-5)
Stroke (serious)
Myocardial infarction (serious)
Blood pressure increased
Heart rate increased
Psychiatric symptom NOS
Psychotic symptom
Manic symptom
Growth suppression
Vascular disorders
Raynaud's phenomenon
Serotonin syndrome
Sources: Page: p.1
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Other AEs: Decreased appetite, Dry mouth...
Other AEs:
Decreased appetite (below serious, 8 patients)
Dry mouth (below serious, 7 patients)
Insomnia (below serious, 10 patients)
Irritability (below serious, 3 patients)
Diaphoresis (below serious, 2 patients)
Libido decreased (below serious, 2 patients)
Tinnitus (below serious, 2 patients)
Muscle tension (below serious, 4 patients)
Tachycardia (below serious, 3 patients)
Paresthesia (below serious, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Decreased appetite 0.86%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 13 - 17
n = 233
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 13 - 17
Sex: M+F
Population Size: 233
Sources: Page: p.8
Insomnia 0.86%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 13 - 17
n = 233
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 13 - 17
Sex: M+F
Population Size: 233
Sources: Page: p.8
Irritability 1.3%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 13 - 17
n = 233
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 13 - 17
Sex: M+F
Population Size: 233
Sources: Page: p.8
Hypertension Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Tachycardia Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Tachypnea Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Delirium acute
Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Creatine kinase increased mild
Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Anxiety 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Dyspnea 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Headache 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Hypertension 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Irritability 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Tachycardia 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Insomnia 2%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Insomnia 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Psychomotor hyperactivity 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Rash 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Tic 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Ventricular hypertrophy 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Vomiting 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Nasopharyngitis below serious, 2 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Decreased appetite below serious, 29 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Weight decreased below serious, 3 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Fatigue below serious, 4 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Irritability below serious, 6 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Insomnia below serious, 7 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Nausea below serious, 1 patient
20 mg single, oral
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Nausea below serious, 1 patient
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Vomiting below serious, 2 patients
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Headache below serious, 4 patients
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Headache below serious, 2 patients
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Nausea below serious, 2 patients
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Feeling jittery below serious, 10 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Insomnia below serious, 10 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Headache below serious, 20 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Dry mouth below serious, 25 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Decreased appetite below serious, 26 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Anorexia below serious, 4 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Heart rate increased below serious, 4 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Libido decreased below serious, 4 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Hyperhidrosis below serious, 5 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Upper respiratory tract infection below serious, 5 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Diarrhea below serious, 6 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Fatigue below serious, 6 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Initial insomnia below serious, 8 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Irritability below serious, 8 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Weight decreased below serious, 8 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Abuse Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Blood pressure increased Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Dependence Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Growth suppression Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Heart rate increased Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Manic symptom Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Psychiatric symptom NOS Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Psychotic symptom Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Raynaud's phenomenon Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Serotonin syndrome Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Vascular disorders Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Cardiovascular disorder (NOS) grade 3-5
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Myocardial infarction serious
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Stroke serious
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Insomnia below serious, 10 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Diaphoresis below serious, 2 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Libido decreased below serious, 2 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Paresthesia below serious, 2 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Tinnitus below serious, 2 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Irritability below serious, 3 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Tachycardia below serious, 3 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Muscle tension below serious, 4 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Dry mouth below serious, 7 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Decreased appetite below serious, 8 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely (co-administration study)
Comment: Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism; concomitant use of DEXEDRINE and CYP2D6 inhibitors may increase the exposure of DEXEDRINE;
Page: 4.0
no
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effect of amphetamine on the expression of the metabotropic glutamate receptor 5 mRNA in developing rat brain.
2000 Dec
Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study.
2001
Anorectic drugs and pulmonary hypertension from the bedside to the bench.
2001 Apr
Effect of 6-hydroxydopamine or repeated amphetamine treatment on mesencephalic mRNA levels for AMPA glutamate receptor subunits in the rat.
2001 Apr 20
Nicotine sensitization increases dendritic length and spine density in the nucleus accumbens and cingulate cortex.
2001 Apr 27
Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity.
2001 Apr 27
Neural mechanisms of motion sickness.
2001 Feb
Entopeduncular lesions facilitate and thalamic lesions depress spontaneous and drug-evoked motor behavior in the hemiparkinsonian rat.
2001 Jun 1
Analysis of amphetamine and congeners in illicit samples by liquid chromatography and capillary electrophoresis.
2001 Mar
Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
2001 May
Amphetamine normalizes the electrical activity of dopamine neurons in the ventral tegmental area following prenatal ethanol exposure.
2001 May
Chronic amphetamine exposure during the preweanling period does not affect avoidance learning or novelty-seeking of adult rats.
2001 May
Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene.
2001 May 1
Genes in drug abuse.
2001 May 1
Post-training injections of catecholaminergic drugs do not modulate fear conditioning in rats and mice.
2001 May 4
Lisdexamfetamine.
2007
An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes.
2007 Jan
Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule.
2007 May 3
Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.
2007 Nov 1
Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician.
2008
Lisdexamfetamine: a prodrug stimulant for ADHD.
2008 Aug
Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.
2008 Jan
Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes.
2008 Jan 8
Poison centers detect an unexpectedly frequent number of adverse drug reactions to lisdexamfetamine.
2008 Jul
Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.
2008 Mar
Lisdexamfetamine dimesylate for childhood ADHD.
2008 May
Attention-deficit-hyperactivity disorder and reward deficiency syndrome.
2008 Oct
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
2008 Sep
Alopecia following initiation of lisdexamfetamine in a pediatric patient.
2009
Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient considerations and the role of lisdexamfetamine.
2009
Psychopharmacology of ADHD in pediatrics: current advances and issues.
2009
Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults.
2009
Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.
2009 Apr
Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder.
2009 Aug 3
The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.
2009 Dec
Case histories in pharmaceutical risk management.
2009 Dec 1
An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
2009 Jun
Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.
2009 Jun
A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.
2009 Jun 9
Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder.
2009 Nov 15
Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults.
2009 Oct
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
2010
Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
2010 Dec
Eosinophilic hepatitis in an adolescent during lisdexamfetamine dimesylate treatment for ADHD.
2010 Jun
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine.
2010 Jun 24
Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
2010 Jun 24
New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children.
2010 May 25
Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry.
2010 Nov
Use of psychostimulants in patients with dementia.
2010 Oct
Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?
2010 Sep
Patents

Sample Use Guides

Attention-deficit/hyperactivity disorder: Initial: 30 mg once daily in the morning; may increase in increments of 10 mg or 20 mg at weekly intervals until optimal response is obtained; maximum: 70 mg/day. Binge eating disorder: Initial: 30 mg once daily in the morning; may titrate in increments of 20 mg at weekly intervals to target dose of 50 to 70 mg once daily (maximum: 70 mg/day).
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The action of several concentrations of d-amphetamine on the NADH-tetrazolium reductase histochemical reaction has been studied in several nervous regions of rats. The facts observed have demonstrated that d-amphetamine increases the intensity of the histochemical reaction by its action on NADH-oxido-reductase activity in all nervous regions studied.
Incubation of lisdexamfetamine in microsomal suspensions at concentrations ranging from 0.01 to 100 M showed no concentration-dependent inhibition for any of the isoenzymes under investigation (CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A, CYP3A4).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:10:58 GMT 2023
Edited
by admin
on Fri Dec 15 15:10:58 GMT 2023
Record UNII
JJ768O327N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXTROAMPHETAMINE SULFATE
MI   ORANGE BOOK   USP   VANDF  
Common Name English
(+)-.ALPHA.-METHYLPHENETHYLAMINE SULFATE (2:1)
Systematic Name English
DEXAMPHETAMINE SULFATE
Common Name English
DEXTROAMPHETAMINE SULFATE [VANDF]
Common Name English
DEXTROAMPHETAMINE SULPHATE
Common Name English
NSC-27104
Code English
(+)-.ALPHA.-METHYLPHENETHYLAMINE SULPHATE (2:1)
Systematic Name English
DELCOBESE COMPONENT DEXTROAMPHETAMINE SULFATE
Common Name English
DEXAMPEX
Brand Name English
DEXTROAMPHETAMINE SULFATE CII
USP-RS  
Common Name English
DEXTROAMPHETAMINE SULFATE CII [USP-RS]
Common Name English
Dexamfetamine sulfate [WHO-DD]
Common Name English
DEXTROAMPHETAMINE SULFATE COMPONENT OF DELCOBESE
Common Name English
DEXTROAMPHETAMINE SULFATE [ORANGE BOOK]
Common Name English
DEXTROAMPHETAMINE SULFATE [MI]
Common Name English
DEXTROSTAT
Brand Name English
DEXEDRINE
Brand Name English
BENZENEETHANAMINE, .ALPHA.-METHYL-, (S)-, SULPHATE (2:1)
Systematic Name English
DEXTROAMPHETAMINE SULFATE [USP MONOGRAPH]
Common Name English
BENZENEETHANAMINE, .ALPHA.-METHYL-, (S)-, SULFATE (2:1)
Systematic Name English
D-AMPHETAMINE HEMISULFATE SALT
Common Name English
FERNDEX
Brand Name English
DEXAMFETAMINE SULFATE [MART.]
Common Name English
DEXAMFETAMINE SULFATE
MART.   WHO-DD  
Common Name English
DEXAMPHETAMINE SULPHATE
Common Name English
DEXAMFETAMINE SULFATE [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C47795
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
DEA NO. 1100
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
EPA PESTICIDE CODE 600091
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID2057865
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
CHEBI
51064
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
EVMPD
SUB01624MIG
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
DRUG BANK
DBSALT000046
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
FDA UNII
JJ768O327N
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
RS_ITEM_NUM
1180004
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
PUBCHEM
5825
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
RXCUI
3287
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C47482
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-111-6
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
NSC
27104
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
ChEMBL
CHEMBL612
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
CAS
51-63-8
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
CAS
20751-44-4
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
NON-SPECIFIC STOICHIOMETRY
MERCK INDEX
m4226
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY Merck Index
SMS_ID
100000092383
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
DAILYMED
JJ768O327N
Created by admin on Fri Dec 15 15:10:58 GMT 2023 , Edited by admin on Fri Dec 15 15:10:58 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY